JP2023533030A5 - - Google Patents
Info
- Publication number
- JP2023533030A5 JP2023533030A5 JP2023501079A JP2023501079A JP2023533030A5 JP 2023533030 A5 JP2023533030 A5 JP 2023533030A5 JP 2023501079 A JP2023501079 A JP 2023501079A JP 2023501079 A JP2023501079 A JP 2023501079A JP 2023533030 A5 JP2023533030 A5 JP 2023533030A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063049768P | 2020-07-09 | 2020-07-09 | |
| US63/049,768 | 2020-07-09 | ||
| PCT/US2021/040802 WO2022011086A1 (en) | 2020-07-09 | 2021-07-08 | Dosage and administration of anti-c5 antibodies for treating paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023533030A JP2023533030A (ja) | 2023-08-01 |
| JP2023533030A5 true JP2023533030A5 (https=) | 2025-10-03 |
| JPWO2022011086A5 JPWO2022011086A5 (https=) | 2025-10-03 |
Family
ID=77127113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023501079A Pending JP2023533030A (ja) | 2020-07-09 | 2021-07-08 | 小児患者において発作性夜間血色素尿症（ｐｎｈ）を治療するための抗ｃ５抗体の投薬量及び投与 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20230235035A1 (https=) |
| EP (2) | EP4295905A1 (https=) |
| JP (1) | JP2023533030A (https=) |
| WO (1) | WO2022011086A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019517473A (ja) | 2016-05-27 | 2019-06-24 | アレクシオン ファーマシューティカルズ インコーポレイテッドＡｌｅｘｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 難治性全身型重症筋無力症の処置のための方法 |
| US12404320B2 (en) | 2018-05-31 | 2025-09-02 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) in pediatric patients |
| CN112996561A (zh) | 2018-10-30 | 2021-06-18 | 亚力兄制药公司 | 用于治疗阵发性睡眠性血红蛋白尿症(pnh)的抗c5抗体的皮下剂量和施用 |
| WO2024227120A1 (en) * | 2023-04-27 | 2024-10-31 | Alexion Pharmaceuticals, Inc. | Systems and methods for monitoring quality of life (qol) features in pnh patients treated with complement pathway inhibitors |
| EP4705337A1 (en) * | 2023-05-02 | 2026-03-11 | Alexion Pharmaceuticals, Inc. | Pediatric dosage and administration of anti-c5 antibodies for treatment of complement disorders |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| PY09026846A (es) | 2008-08-05 | 2015-09-01 | Novartis Ag | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5 |
| NZ631007A (en) | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| CN107207607B (zh) * | 2014-12-19 | 2021-05-04 | 中外制药株式会社 | 抗-c5抗体及使用方法 |
| ES2984352T3 (es) * | 2016-06-14 | 2024-10-29 | Regeneron Pharma | Anticuerpos anti-C5 y usos de los mismos |
| US12404320B2 (en) * | 2018-05-31 | 2025-09-02 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) in pediatric patients |
-
2021
- 2021-07-08 JP JP2023501079A patent/JP2023533030A/ja active Pending
- 2021-07-08 EP EP23193515.6A patent/EP4295905A1/en active Pending
- 2021-07-08 US US18/011,807 patent/US20230235035A1/en active Pending
- 2021-07-08 EP EP21748759.4A patent/EP4178674A1/en not_active Withdrawn
- 2021-07-08 WO PCT/US2021/040802 patent/WO2022011086A1/en not_active Ceased